The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B
Open accessAbstract
BACKGROUND: We describe severe and unexpected multisystem toxicity that occurred during a study of the antiviral nucleoside analogue fialuridine (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil, or FIAU) as therapy for chronic hepatitis B virus infection. METHODS: Fifteen patients with chronic hepatitis B were randomly assigned to receive fialuridine at a dose of either 0.10 or 0.25 mg per kilogram of body weight per day for 24 weeks and were monitored every 1 to 2 weeks by means of a physical examination, blood tests, and testing for hepatitis B virus markers. RESULTS: During the 13th week lactic acidosis and liver failure suddenly developed in one patient. The study was terminated on an emergency basis, and all treatment with fialuridine was discontinued. Seven patients were found to have severe hepatotoxicity, with progressive lactic acidosis, worsening jaundice, and deteriorating hepatic synthetic function despite the discontinuation of fialuridine. Three other patients had mild hepatotoxicity. Several patients also had pancreatitis, neuropathy, or myopathy. Of the seven patients with severe hepatotoxicity, five died and two survived after liver transplantation. Histologic analysis of liver tissue revealed marked accumulation of microvesicular and macrovesicular fat, with minimal necrosis of hepatocytes or architectural changes. Electron microscopy showed abnormal mitochondria and the accumulation of fat in hepatocytes. CONCLUSIONS: In patients with chronic hepatitis B, treatment with fialuridine induced a severe toxic reaction characterized by hepatic failure, lactic acidosis, pancreatitis, neuropathy, and myopathy. This toxic reaction was probably caused by widespread mitochondrial damage and may occur infrequently with other nucleoside analogues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fialuridine (Section 7.1) and troglitazone (Section 7.4) are intrinsic toxicodynamic failures, driven by human-relevant mitochondrial injury and reactive-metabolite formation, respectively.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fialuridine, an antiviral nucleoside analogue, caused catastrophic hepatic failure and lactic acidosis in a 1993 clinical trial, resulting in five deaths and two liver transplantations.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies across multiple species showed no indication of the severe mitochondrial toxicity observed in humans, because fialuridine’s incorporation into mitochondrial DNA is mediated by a human-specific mitochondrial transporter [69,70].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fourth, idiosyncratic toxicities, such as those underlying the fialuridine and troglitazone failures, are by definition not captured by any pharmacokinetic scaling framework, and even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76]”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Even a pilot study on 43 patients treated for 2 and 4 weeks duration with Fialuridine did not reveal any signs of hepatic toxicity on initial examination.[17]”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“During 13th week of phase II studies, one of the patients suddenly developed hepatic toxicity and lactic acidosis. At this point, trial was stopped for all other patients.”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Even after discontinuation of Fialuridine administration, seven other patients showed signs of severe hepatic toxicity five of which could not survive and other two could survive only after liver transplantation.[17]”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, D., Cheung, A. M., O'Rourke, K., Naylor, C. D., Detsky, A. S., & Heathcote, J. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-4-199308150-00011 · Cited by 974
Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C., Lindsay, K. L., Payne, J., Dienstag, J. L., O'Brien, C., Tamburro, C. H., Jacobson, I. M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008023230503 · Cited by 838
Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy
Dalakas, M. C., Illa, I., Pezeshkpour, G. H., Laukaitis, J. P., Cohen, B. H., & Griffin, J. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004193221602 · Cited by 837
Doong, S.-L., Tsai, C. H., Schinazi, R. F., Liotta, D. C., & Cheng, Y. C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8495 · Cited by 513
Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy
Arnaudo, E., Shanske, S., DiMauro, S., Schon, E. A., Moraes, C. T., Schon, E. A., & Dalakas, M. C. (1991) · The Lancet · doi:10.1016/0140-6736(91)91294-5 · Cited by 504
Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B
Hoofnagle, J. H., Peters, M. G., Mullen, K. D., Jones, D. B., Rustgi, V. K., Bisceglie, A. M. D., Hallahan, C. W., Park, Y., Meschievitz, C., & Jones, E. A. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90367-8 · Cited by 420
Self-citationReversal of Fulminant Hepatic Failure Using An Extracorporeal Liver Assist Device
Sussman, N., Chong, M. G., Koussayer, T., He, D.-E., Shang, T. A., Whisennand, H. H., & Kelly, J. H. (1992) · Hepatology · doi:10.1002/hep.1840160112 · Cited by 341
Chen, C., Vazquez-Padua, M. A., & Cheng, Y. C. (1991) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11067-5 · Cited by 296
A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
Lok, A. S.-F., Wu, P., Lai, C., Lau, J. Y. N., Leung, E. K. Y., Wong, L. S. K., Ma, O. C. K., Lauder, I. J., Ng, C. P. L., & Chung, H.-T. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90337-x · Cited by 239
Hodge, R. A. V., Sutton, D., Boyd, M. R., Harnden, M. R., & Jarvest, R. L. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1765 · Cited by 207
Research works printed but not linked: 7
- Dusheiko G, Hoofnagle JH. Hepatitis B. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, eds. Oxford textbook of clinical hepatology. New York: Oxford University Press, 1991:571-92.
- Paar DP, Hooten TM, Smiles KA, et al. The effect of FIAU on chronic hepatitis B virus (HBV) infection in HIV-infected subjects (ACTG 122b). In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., October 10–14, 1992. Washington, D.C.: American Society for Microbiology, 1992:264. abstract.
- 10.1002/hep.1840160402 · DOI
- Stevenson W, 1995, Transplant Proc, 27, 1219
- Chen CH, 1991, Mol Pharmacol, 39, 625
- Klecker RW, 1994, Mol Pharmacol, 46, 1204
- Maxson CJ, 1992, Am J Gastroenterol, 87, 708
Cited by
Sorted by citations
Lee, W. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372406 · Cited by 2,559
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Adverse effects of antiretroviral therapy
Carr, A. D., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,076
The Treatment of Chronic Viral Hepatitis
Hoofnagle, J. H., & Bisceglie, A. M. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701303360507 · Cited by 942
Self-citationAdverse effects of reverse transcriptase inhibitors
Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A. M., & Koopmans, P. P. (1998) · AIDS · doi:10.1097/00002030-199814000-00004 · Cited by 842
A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332501 · Cited by 794
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
Mitochondrial disorders as windows into an ancient organelle
Vafai, S. B., & Mootha, V. K. (2012) · Nature · doi:10.1038/nature11707 · Cited by 733
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
Self-citationRespiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment
Griffiths, C. D., Drews, S. J., & Marchant, D. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-16 · Cited by 627
Mitochondria as a Target of Environmental Toxicants
Meyer, J. N., Leung, M. C. K., Rooney, J. P., Sendoel, A., Hengartner, M. O., Kisby, G. E., & Bess, A. S. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft102 · Cited by 587
Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients
Côté, H. C. F., Brumme, Z. L., Craib, K. J. P., Alexander, C. S., Wynhoven, B., Ting, L. S. L., Wong, H., Harris, M., Harrigan, P. R., O’Shaughnessy, M. V., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012035 · Cited by 568
Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective
Lewis, W., Day, B. J., & Copeland, W. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1201 · Cited by 496
Pirmohamed, M., Breckenridge, A., Kitteringham, N. R., & Park, B. K. (1998) · BMJ · doi:10.1136/bmj.316.7140.1295 · Cited by 457
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
Birkuš, G., Hitchcock, M. J. M., & Cihlář, T. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.716-723.2002 · Cited by 436
Perrillo, R. P. (2001) · Gastroenterology · doi:10.1053/gast.2001.22461 · Cited by 416
DNA Polymerase γ, The Mitochondrial Replicase
Kaguni, L. S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161455 · Cited by 414
Mitochondrial dysfunction in cardiovascular disease
Ballinger, S. W. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.02.014 · Cited by 405
Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase
Johnson, A. A., Ray, A. S., Hanes, J. W., Suo, Z., Colacino, J. M., Anderson, K. S., & Johnson, K. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106743200 · Cited by 399
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
Cihlář, T., & Ray, A. S. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.014 · Cited by 390
Imaging Transgene Expression with Radionuclide Imaging Technologies
Gambhir, S. S., Herschman, H. R., Cherry, S. R., Barrio, J. R., Satyamurthy, N., Toyokuni, T., Phelps, M. E., Larson, S. M., Balatoni, J., Finn, R., et al. (2000) · Neoplasia · doi:10.1038/sj.neo.7900083 · Cited by 353
Long-term therapy of chronic hepatitis B with lamivudine
Lau, D., Khokhar, F., Doo, E. C., Ghany, M. G., Herion, D. W., Park, Y., Kleiner, D. E., Schmid, P., Condreay, L. D., Gauthier, J., et al. (2000) · Hepatology · doi:10.1053/jhep.2000.17912 · Cited by 345
Self-citationTjuvajev, J. G., Finn, R., Watanabe, K. A., Joshi, R., Oku, T., Kennedy, J. D., Beattie, B. J., Koutcher, J. A., Larson, S. M., & Blasberg, R. G. (1996) · PubMed · Cited by 332
Antisense technology: A review
Crooke, S. T., Liang, X., Baker, B. F., & Crooke, R. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100416 · Cited by 350
Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity
Walgren, J. L., Mitchell, M. D., & Thompson, D. C. (2005) · Critical Reviews in Toxicology · doi:10.1080/10408440590935620 · Cited by 322
Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection
Lafeuillade, A., Hittinger, G., & Chadapaud, S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03618-7 · Cited by 315
Lee, W. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331706 · Cited by 305
Balfour, H. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904223401608 · Cited by 286
Central role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
Mechanisms of drug-induced liver injury: from bedside to bench
Tujios, S. R., & Fontana, R. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.22 · Cited by 277
Side effects of long-term oral antiviral therapy for hepatitis B
Fontana, R. J. (2009) · Hepatology · doi:10.1002/hep.22885 · Cited by 272
Drug–Induced Liver Injury: Mechanisms and Test Systems
Bissell, M. D., Gores, G. J., Laskin, D. L., & Hoofnagle, J. H. (2001) · Hepatology · doi:10.1053/jhep.2001.23505 · Cited by 265
Self-citationChariot, P., Drogou, I., de Lacroix-Szmania, I., Eliezer‐Vanerot, M., Chazaud, B., Lombès, A., Schaeffer, A., & Zafrani, É. S. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80020-8 · Cited by 259
Weaver, R. J., Blomme, E. A. G., Chadwick, A. E., Copple, I. M., Gerets, H. H. J., Goldring, C. E., Guillouzo, A., Hewitt, P. G., Ingelman‐Sundberg, M., Jensen, K. G., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0048-x · Cited by 261
TGN1412: From Discovery to Disaster
Attarwala, H. (2010) · Journal of Young Pharmacists · doi:10.4103/0975-1483.66810 · Cited by 253
Mechanistic Basis of Enzyme-Targeted Drugs
Robertson, J. G. (2005) · Biochemistry · doi:10.1021/bi050247e · Cited by 247
Lauschke, V. M., Hendriks, D. F. G., Bell, C. C., Andersson, T. B., & Ingelman-Sundberg, M. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00150 · Cited by 241
Mitochondrial abnormalities—A link to idiosyncratic drug hepatotoxicity?
Boelsterli, U. A., & Lim, P. L. K. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.12.013 · Cited by 232
RNA interference in the era of nucleic acid therapeutics
Jadhav, V., Vaishnaw, A. K., Fitzgerald, K. J., & Maier, M. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02105-y · Cited by 232
Lee, H., Hanes, J. W., & Johnson, K. A. (2003) · Biochemistry · doi:10.1021/bi035596s · Cited by 218
Antiretroviral drugs and liver injury
Soriano, V., Puoti, M., García‐Gascó, P., Rockstroh, J. K., Benhamou, Y., Barreiro, P., & McGovern, B. (2008) · AIDS · doi:10.1097/qad.0b013e3282f0e2fd · Cited by 215
Neurologic Manifestations of HIV Infection
Simpson, D. M., & Tagliati, M. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-10-199411150-00008 · Cited by 212
Lactic Acidosis and Hepatic Steatosis Associated with Use of Stavudine: Report of Four Cases
Miller, K. D., Cameron, M., Wood, L. V., Dalakas, M. C., & Kovacs, J. A. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-3-200008010-00010 · Cited by 206
A human liver organoid screening platform for DILI risk prediction
Zhang, C. J., Meyer, S. R., O’Meara, M. J., Huang, S., Capeling, M. M., Ferrer-Torres, D., Childs, C. J., Spence, J. R., Fontana, R. J., & Sexton, J. Z. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.019 · Cited by 203
Moyle, G. J. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80064-8 · Cited by 192
Bock, C. –., Tillmann, H. L., Torresi, J., Klempnauer, J. L., Locarnini, S., Manns, M. P., & Trautwein, C. (2002) · Gastroenterology · doi:10.1053/gast.2002.31015 · Cited by 189
Vorrink, S. U., Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy058 · Cited by 187
Fluorinated nucleosides: Synthesis and biological implication
Liu, P., Sharon, A., & Chu, C. K. (2008) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2008.06.007 · Cited by 181
Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights
Götte, M., & Feld, J. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.60 · Cited by 179
Antiviral l -Nucleosides Specific for Hepatitis B Virus Infection
Bryant, M. L., Bridges, E. G., Placidi, L., Faraj, A., Loi, A.-G., Pierra, C., Dukhan, D., Gosselin, G., Imbach, J., Hernandez, B. Y., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.229-235.2001 · Cited by 179
Hepatitis B: diagnosis, prevention, and treatment
Gitlin, N. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.8.1500 · Cited by 180
Lewis, J. H. (2000) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70287-x · Cited by 176
Fromenty, B., Berson, A., & Pessayre, D. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)82328-8 · Cited by 175
Lewis, W., Copeland, W. C., & Day, B. J. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780288 · Cited by 173
Vorrink, S. U., Ullah, S., Schmidt, S., Nandania, J., Velagapudi, V., Beck, O., Ingelman‐Sundberg, M., & Lauschke, V. M. (2017) · The FASEB Journal · doi:10.1096/fj.201601375r · Cited by 172
Chapman, L. E., MERTZ, G. J., Peters, C. J., Jolson, H. M., Khan, A. S., Ksiazek, T. G., Koster, F. T., Baum, K. F., Rollin, P. E., Pavia, A. T., et al. (1999) · Antiviral Therapy · doi:10.1177/135965359900400404 · Cited by 170
Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium
Malik, A. H., & Lee, W. M. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-9-200005020-00007 · Cited by 162
de Man, R. A., Wolters, L. M. M., Nevens, F., Chua, D., Sherman, M., Lai, C. L., Gadano, A. C., Lee, Y., Mazzotta, F., Thomas, N., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.26815 · Cited by 160
Pankiewicz, K. W. (2000) · Carbohydrate Research · doi:10.1016/s0008-6215(00)00089-6 · Cited by 158
Rompay, A. R. V., Johansson, M., & Karlsson, A. (2003) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.07.001 · Cited by 158
A brief overview of mechanisms of mitochondrial toxicity from NRTIs
Kohler, J. J., & Lewis, W. (2006) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20223 · Cited by 157
Heart Failure in Patients With Human Immunodeficiency Virus Infection
Remick, J. S., Georgiopoulou, V. V., Marti, C. N., Ofotokun, I., Kalogeropoulos, A. P., Lewis, W., & Butler, J. (2014) · Circulation · doi:10.1161/circulationaha.113.004574 · Cited by 151
Cho, T., & Uetrecht, J. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00357 · Cited by 151
Baudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00768g · Cited by 150
Patel, V. A., & Sanyal, A. J. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.012 · Cited by 151
Mechanisms of Adverse Drug Reactions
Pirmohamed, M. (2014) · Wiley eBooks · doi:10.1002/9781118820186.ch30 · Cited by 150
Crignis, E. D., Hossain, T., Romal, S., Carofiglio, F., Moulos, P., Khalid, M. M., Rao, S., Bazrafshan, A., Verstegen, M. M. A., Pourfarzad, F., et al. (2021) · eLife · doi:10.7554/elife.60747 · Cited by 155
Lai, Y., Tse, C., & Unadkat, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307938200 · Cited by 149
Jarvis, B., & Faulds, D. M. (1999) · Drugs · doi:10.2165/00003495-199958010-00015 · Cited by 148
Antiretroviral nucleoside and nucleotide analogues and mitochondria
Cossarizza, A., & Moyle, G. J. (2004) · AIDS · doi:10.1097/00002030-200401230-00002 · Cited by 143
Mitochondrial Involvement in Drug-Induced Liver Injury
Pessayre, D., Mansouri, A., Berson, A., & Fromenty, B. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_11 · Cited by 142
Anderson, P. L., Kakuda, T. N., & Lichtenstein, K. A. (2004) · Clinical Infectious Diseases · doi:10.1086/381678 · Cited by 148
Govindarajan, R., Leung, G., Zhou, M., Tse, C., Wang, J., & Unadkat, J. D. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90672.2008 · Cited by 142
Ma, T., Pai, S. B., Zhu, Y. L., Lin, J. S., Shanmuganathan, K., Du, J., Wang, C., Kim, H., Newton, M. G., Cheng, Y. C., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960098l · Cited by 140
Nucleoside Analogues for Chronic Hepatitis B: Antiviral Efficacy and Viral Resistance
Papatheodoridis, G., Dimou, E., & Papadimitropoulos, V. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04175-8 · Cited by 137
Arnold, J. J., Sharma, S. D., Feng, J. Y., Ray, A. S., Smidansky, E. D., Kireeva, M. L., Cho, A., Perry, J. K., Vela, J. E., Park, Y., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003030 · Cited by 135
Self-citationBain, V. G., Kneteman, N. M., Ma, M. M., Gutfreund, K. S., Shapiro, J., Fischer, K., Tipples, G. A., Lee, H., Jewell, L. D., & Tyrrell, D. L. (1996) · Transplantation · doi:10.1097/00007890-199611270-00013 · Cited by 133
Lactic Acidosis Associated with Stavudine Administration: A Report of Five Cases
Mokrzycki, M. H., Harris, C., May, H. T., Laut, J. M., & Palmisano, J. (2000) · Clinical Infectious Diseases · doi:10.1086/313594 · Cited by 131
Insights into the Molecular Mechanism of Mitochondrial Toxicity by AIDS Drugs
Feng, J. Y., Johnson, A. A., Johnson, K. A., & Anderson, K. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101156200 · Cited by 130
Sundar, K., Suarez, M., Banogon, P. E., & Shapiro, J. M. (1997) · Critical Care Medicine · doi:10.1097/00003246-199708000-00034 · Cited by 130
Cloning of the cDNA and Chromosome Localization of the Gene for Human Thymidine Kinase 2
Johansson, M., & Karlsson, A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.13.8454 · Cited by 127
Coghlan, M. E., Sommadossi, J., Jhala, N. C., Many, W. J., Saag, M. S., & Johnson, V. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323783 · Cited by 125
Stuyver, L. J., Lostia, S., Adams, M., Mathew, J. S., Pai, B. S., Grier, J. P., Tharnish, P. M., Choi, Y., Chong, Y., Choo, H., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3854-3860.2002 · Cited by 124
The Woodchuck Model of Hepatitis B Virus Infection
Tennant, B. C., & Gerin, J. L. (2001) · ILAR Journal · doi:10.1093/ilar.42.2.89 · Cited by 123
150 years of pharmacovigilance
Routledge, P. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03148-1 · Cited by 122
Main, J., Brown, J. L., Howells, C., Galassini, R., Crossey, M. M. E., Karayiannis, P., Georgiou, P., Atkinson, G. F., & Thomas, H. C. (1996) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.1996.tb00098.x · Cited by 122
Lampertico, P., Chan, H. L., Janssen, H. L. A., Strasser, S. I., Schindler, R., & Berg, T. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13659 · Cited by 123
Human reporter genes: potential use in clinical studies
Serganova, I. S., Ponomarev, V., & Blasberg, R. G. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.05.009 · Cited by 118
Phosphorylation of Nucleoside Analog Antiretrovirals: A Review for Clinicians
Stein, D. S., & Moore, K. H. P. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.1.11.34439 · Cited by 116
Hoofnagle, J. H. (1998) · Digestion · doi:10.1159/000007532 · Cited by 116
Self-citationLewis, W., Kohler, J. J., Hosseini, S. H., Haase, C. P., Copeland, W. C., Bienstock, R. J., Ludaway, T., McNaught, J., Russ, R. B., Stuart, T., et al. (2006) · AIDS · doi:10.1097/01.aids.0000216367.23325.58 · Cited by 113
Cardiomyopathy in AIDS: A pathophysiological perspective
Lewis, W. (2000) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.2000.9031 · Cited by 113
Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges
Jee, A., Sernoskie, S. C., & Uetrecht, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062954 · Cited by 113
Shen, W., Hoyos, C. L. D., Sun, H., Vickers, T. A., Liang, X., & Crooke, S. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky060 · Cited by 111
Reporter gene imaging: potential impact on therapy
Serganova, I. S., & Blasberg, R. G. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.05.008 · Cited by 110
Liver injury caused by drugs: an update
Stirnimann, G., & Kessebohm, K. (2010) · Swiss Medical Weekly · doi:10.4414/smw.2010.13080 · Cited by 110
Metadata
- Authors
- McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., Pruett, T., Stotka, J. L., Straus, S. E., & Hoofnagle, J. H.
- Affiliations
- National Institutes of Health (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- National Institute of Allergy and Infectious Diseases (US)
- National Cancer Institute (UA)
- University of Virginia Hospital (US)
- Eli Lilly (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-10-26
- Volume
- 333
- Issue
- 17
- Pages
- 1099-1105
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2327070670
- Cited by
- 616
- References
- 39
- Citations by year
- 2026: 14 · 2025: 11 · 2024: 17 · 2023: 13 · 2022: 11 · 2021: 19 · 2020: 13 · 2019: 26 · 2018: 32 · 2017: 23 · 2016: 27 · 2015: 16 · 2014: 12 · 2013: 16 · 2012: 10
- FWCI
- 28.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- NIH Clinical Center
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Keywords
- FIAU, lactic acidosis, liver failure, hepatotoxicity, chronic hepatitis B, nucleoside analogues, drug toxicity, mitochondrial damage, pancreatitis, neuropathy, myopathy, liver transplantation, drug-induced liver injury
- MeSH terms
- Acidosis, Lactic, Adult, Alanine Transaminase, Antiviral Agents, Arabinofuranosyluracil, Chronic Disease, DNA, Mitochondrial, DNA, Viral, Female, Hepatitis B, Humans, Jaundice, Liver, Male, Middle Aged, Pancreatitis, Peripheral Nervous System Diseases, Drugs, Investigational, Liver Transplantation, Liver Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
